The Need For Clarification On Post-Market Requirements For Pediatric Medicines
This article was originally published in SRA
Geneviève Michaux explains why guidance is needed to interpret the post-marketing requirements for drugs under the EU Paediatric Regulation.
You may also be interested in...
ABHI director of value and access Luella Trickett talks about the importance of real-world evidence in product development and value-based procurement in secondary care in the UK.
What will the fall-out of political tensions between the EU and Switzerland mean for notified bodies based in Switzerland, and for the future recognition of CE marks granted in one of the most important medtech markets in Europe?
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.